Latest news with #Omics
Hans India
2 days ago
- Health
- Hans India
2-day conference on ‘Connectomics' begins
CHITTOOR: The 2-day national conference 'Connectomics 2025', focusing on the convergence of Omics, Bioinformatics, and Data Science for modern medical research, was inaugurated on Tuesday at the Apollo Institute of Medical Sciences and Research (AIMSR), Chittoor. Addressing the gathering, Vice-Chancellor of Apollo University Dr H Vinod Bhat said that Genomics and Connectomics will play a crucial role in the future of medicine. He highlighted the growing importance of using these technologies for personalised healthcare and early diagnosis. He further said that public health initiatives must increasingly incorporate genomic screening and vaccination to strengthen immunity and prevent the onset of diseases. CEO of Apollo Knowledge V Sivaramakrishnan noted the increasing relevance of digital health and shared how Apollo is taking a leading step in this space. Patients will soon be able to access their health data via mobile devices and even receive medicines at home. Dr Usha Adiga, Associate Dean at AIMSR, stated that the conference brings together top minds from medical, biotech, and data science key objectives are to strengthen public health through technology and explore new frontiers in medical research. Dignitaries present at the event included Prof M Potharaju (Registrar, The Apollo University), Prof Ravi Mahajan (Director, Research & Innovations, Apollo Hospitals), Dr Suruchi Agarwal, Dr Priyanka Narad (Scientists, ICMR) and Dr Alfred J Agustin (Dean, AIMSR).
The Hindu
3 days ago
- Health
- The Hindu
National conference on modern medical research inaugurated at AIMSR in Chittoor
National conference titled Connectomics-2025, focusing on the convergence of Omics, Bioinformatics, and Data Science for modern medical research, was inaugurated at the Apollo Institute of Medical Sciences and Research (AIMSR) in Chittoor on Tuesday. Dr. H. Vinod Bhat, Vice-Chancellor of Apollo University, inaugurated the two-day conference by lighting the lamp. In his keynote address, he emphasized that Genomics and Connectomics will play a crucial role in the future of medicine. Highlighting the growing importance of using these technologies for personalised healthcare and early diagnosis, he said that public health initiatives must increasingly incorporate genomic screening and vaccination to strengthen immunity and prevent the onset of diseases. Sivarama Krishnan V., CEO of Apollo Knowledge, noted the increasing relevance of digital health and shared how Apollo is taking a leading step in this space. He said that Apollo has already impacted millions of lives and is now working toward digitising every patient's health records. Patients will soon be able to access their health data via mobile devices and even receive medicines at home, he added. He affirmed that education, research, and health care delivery will continue to be the core focus areas of the Apollo group. Dr. Usha Adiga, Associate Dean at AIMSR, said that the conference is a prestigious national-level academic event that brings together top minds from medical, biotech, and data science domains. The key objectives are to strengthen public health through technology and explore new frontiers in medical research. She said that the event includes special sessions on topics such as genomics, proteomics, systems biology, microbiome, metabolomics, and pharmacogenomics, all of which are highly relevant to current medical research. Poster and oral presentation sessions have been arranged for students and young researchers. The conference witnessed participation from numerous experts, researchers, and students in the fields of medicine, biotechnology, and data science from across the country. International and national experts from various institutions will deliver presentations.
Time of India
05-07-2025
- Science
- Time of India
BBAU offers MSc bioinfo course
Lucknow: Babasaheb Bhimrao Ambedkar University has invited registration from CUET and non-CUET candidates for admission to its MSc bioinformatics course. "MSc bioinformatics programme is an interdisciplinary course that offers a comprehensive curriculum combining biology, data analytics and computer science. The course duration is two years, split into four semesters," said a BBAU official. He said students would learn advanced computational methods, genomics and data analysis. It equips students with genomics and proteomics, molecular modelling and drug design, artificial intelligence in life sciences, database management, programming and machine learning for Omics data. The university provides state-of-the-art laboratories and research facilities.
The Hindu
07-05-2025
- Science
- The Hindu
Symposium on recent trends in Omics at ICAR-IISR headquarters in Kozhikode
ICAR–Indian Institute of Spices Research (IISR) is hosting a National Symposium on 'Recent Trends in Omics in Plant Biology' from May 20 to 22 at its headquarters in Kozhikode. The event is being organised by the institute's Bioinformatics and Integrative Genomics Facility, with financial assistance from the Department of Biotechnology, Ministry of Science and Technology. The symposium is expected to bring together scientists, academicians, research scholars, and industry representatives from across the country to deliberate on the rapidly evolving field of Omics technologies and their applications in plant science and agriculture. It will feature plenary lectures by leading experts, technical paper presentations, and panel discussions covering a spectrum of themes. These include genomics, transcriptomics, proteomics, metabolomics, and bioinformatics. Sessions will also explore genome editing technologies, horti-informatics, and the role of artificial intelligence and computational tools in advancing plant research and sustainable agriculture. The event is open to scientists, faculty members, postgraduate and doctoral scholars, and professionals from the agri-biotech and bioinformatics industry. Interested participants are required to register through the institute's official website. The last date for registration for the symposium is May 12. The institute is also organising a pre-symposium workshop on May 20, to provide hands-on training in Omics tools and data analysis techniques in transcriptomics, computational metagenomics, Genome wide association studies and machine learning. There will be a separate registration for the pre-symposium workshop. For further information, participants may contact the organising committee at 0495-2731410 or visit the official IISR website -
Yahoo
13-02-2025
- Business
- Yahoo
QIAGEN Strengthens Global Bioinformatics Leadership With New Data Center in Australia/Asia-Pacific Region
New facility reflects QIAGEN's commitment to enhancing its bioinformatics data center infrastructure in the Australia, New Zealand, New Guinea and surrounding islands region New data center in Melbourne meets Australian regulations to ensure quality, scalable and trustworthy support for Omics analysis and interpretation in genomic testing labs Expands a QIAGEN network of seven data centers around the globe designed to ensure highest level of data security, compliance and operational excellence worldwide VENLO, The Netherlands & REDWOOD CITY, Calif., February 13, 2025--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the official opening of a new data center in Melbourne, Australia, designed to strengthen its global bioinformatics leadership position in this region of the world. This latest addition reflects QIAGEN's ongoing commitment to enhance its bioinformatics data infrastructure, enabling initiatives to broaden the reach and use of bioinformatics products in the Australia/Asia-Pacific region – which encompasses Australia, New Zealand, New Guinea and surrounding islands. It will also expand the current QIAGEN network of seven data centers strategically located across the United States, United Kingdom, Denmark, Turkey, South Korea, Japan and China. This investment supports the expanding data center market in the Australia/Asia-Pacific region while ensuring local compliance and high-quality solutions for Omics analysis and interpretation in genomic testing laboratories. The new Melbourne facility will provide in-country data hosting, supporting genomic testing labs in Australia to securely host sensitive data while complying with Australian privacy and health data regulations. It underscores QIAGEN's commitment to providing tailored bioinformatics solutions that enable secure, efficient and innovative clinical and diagnostic services. "With the opening of this data center, we are strengthening our ability to serve the Australian market and the broader Australia/Asia-Pacific region," said Dominic John, Vice President, QIAGEN Digital Insights. "This new facility will allow diagnostic labs to confidently deliver clinical next-generation sequencing testing services while meeting evolving data sovereignty laws. Now operating eight data centers around the globe, we are ensuring data security, compliance and operational excellence worldwide." As the use of clinical next-generating sequencing (NGS) continues to evolve, QIAGEN remains at the forefront, delivering innovative bioinformatics solutions that empower labs and researchers to unlock the full potential of genomics and personalized medicine. With over 25 years of experience in the industry, 90,000 users worldwide, and 4 million profiled patient cases, QDI is committed to accelerating breakthroughs in science and healthcare by providing intuitive, scalable solutions that transform complex biological information into clear, actionable insights. For more information about QIAGEN Digital Insights and its global data infrastructure, visit About QIAGEN QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of December 31, 2024, QIAGEN employed more than 5,700 people in over 35 locations worldwide. For more information, visit Forward-Looking Statement Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and / or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results - such as expected adjusted net sales and adjusted diluted earnings - are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, regulatory processes and logistical dependencies), variability in operating results and allocations between customer classes, commercial development for our products to customers in the Life Sciences and clinical healthcare, changes in relationships with customers, suppliers or strategic partners; competition and rapid technological advancements; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining regulatory approvals for our products; difficulties in successfully adapting QIAGEN's products into integrated solutions and producing these products; and protecting product differentiation from competitors. Additional uncertainties may arise from market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other "force majeure" events. There is also no guarantee that anticipated benefits from acquisitions will materialize as expected. For a comprehensive overview of risks, please refer to the "Risk Factors" contained in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission. Source: QIAGEN N.V. Category: Corporate View source version on Contacts Contacts QIAGEN: Investor Relations John Gilardi +49 2103 29 11711Domenica Martorana +49 2103 29 11244e-mail: ir@ Public Relations Thomas Theuringer +49 2103 29 11826Lisa Specht +49 2103 29 14181e-mail: pr@ Sign in to access your portfolio
